Temporal trend of drug-resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals

This publication has 27 references indexed in Scilit:

• Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants
  Clinical Microbiology and Infection, 2016
• Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study^*
  HIV Research & Clinical Practice, 2016
• Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia
  Journal of Clinical Microbiology, 2015
• Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments
  AIDS, 2014
• E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure
  AIDS, 2012
• APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon
  PLOS Genetics, 2012
• Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication
  HIV Medicine, 2012
• Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia
  Journal of Antimicrobial Chemotherapy, 2011
• APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA
  Retrovirology, 2009
• Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
  Nature, 2003